Equity Profile

RDY

Dr. Reddy's Laboratories Limited

Health CarePharmaceuticals$10.3B

May12Tue

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Dr. Reddy's Laboratories Limited is a major player in the pharmaceuticals sector, focusing on producing a wide range of medications and healthcare products....

Key Metrics to Watch

Revenue Growth

This metric will indicate how well the company is expanding its sales, which is crucial for assessing overall performance.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be keen to see if the company can deliver strong earnings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Dr. Reddy's Laboratories Limited is a major player in the pharmaceuticals sector, focusing on producing a wide range of medications and healthcare products. With a market cap of $10 billion, the company is significant in the healthcare industry, especially as global demand for affordable medications continues to rise.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

In the last quarter, Dr. Reddy's continued to navigate challenges in the pharmaceutical market but showed resilience in maintaining its product offerings. The company has been focusing on expanding its generics portfolio.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street is cautiously optimistic about Dr. Reddy's upcoming earnings report, particularly regarding revenue growth and profitability metrics. Investors are looking for signs of recovery in key markets.

Bull Case

If Dr. Reddy's can demonstrate significant revenue growth and improved margins, it could signal a strong recovery and boost investor confidence.

Bear Case

Conversely, if the company reports disappointing earnings or weak guidance, it could raise concerns about its competitive position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate in key markets?

This will help investors understand the company's performance and market demand, which are critical for future growth.

How is the company addressing competition in the generics market?

Insights on competitive strategies will be crucial for assessing Dr. Reddy's ability to maintain or grow its market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dr. Reddy's potential for revenue growth due to its expanding generics portfolio and strategic market positioning.

Supporting Evidence

Options are pricing an 8.11% move, indicating expectations of volatility that may not align with historical performance.

The company's historical resilience in challenging markets suggests it could outperform cautious expectations.

Key Risk

If revenue growth exceeds 10%, it could significantly shift market sentiment and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around Dr. Reddy's ability to grow revenue in a challenging market environment.

Bull Confirmed If

A revenue growth rate exceeding 10% would confirm the bull case, indicating strong demand for its products.

Bear Confirmed If

A revenue decline or stagnation could confirm the bear case, raising concerns about market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect notable volatility around the earnings report.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests the stock could rise by around 5.5%, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors digest the details.

Miss

If the company misses earnings expectations, history indicates a potential drop of about 4.5%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the generics portfolio expansion and its impact on revenue.
2Details on market share changes in key segments.
3Management's outlook on competition and pricing strategies.
4Insights into cost management and operational efficiencies.
5Any commentary on regulatory challenges or opportunities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

RadNet, Inc.

Company Snapshot

Dr. Reddy's Laboratories Limited is a major player in the pharmaceuticals sector, focusing on producing a wide range of medications and healthcare products....

Key Metrics to Watch

Revenue Growth

This metric will indicate how well the company is expanding its sales, which is crucial for assessing overall performance.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be keen to see if the company can deliver strong earnings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Dr. Reddy's can demonstrate significant revenue growth and improved margins, it could signal a strong recovery and boost investor confidence.

Bear Case

Conversely, if the company reports disappointing earnings or weak guidance, it could raise concerns about its competitive position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate in key markets?

This will help investors understand the company's performance and market demand, which are critical for future growth.

How is the company addressing competition in the generics market?

Insights on competitive strategies will be crucial for assessing Dr. Reddy's ability to maintain or grow its market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dr. Reddy's potential for revenue growth due to its expanding generics portfolio and strategic market positioning.

Supporting Evidence

Options are pricing an 8.11% move, indicating expectations of volatility that may not align with historical performance.

The company's historical resilience in challenging markets suggests it could outperform cautious expectations.

Key Risk

If revenue growth exceeds 10%, it could significantly shift market sentiment and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around Dr. Reddy's ability to grow revenue in a challenging market environment.

Bull Confirmed If

A revenue growth rate exceeding 10% would confirm the bull case, indicating strong demand for its products.

Bear Confirmed If

A revenue decline or stagnation could confirm the bear case, raising concerns about market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect notable volatility around the earnings report.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests the stock could rise by around 5.5%, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors digest the details.

Miss

If the company misses earnings expectations, history indicates a potential drop of about 4.5%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the generics portfolio expansion and its impact on revenue.
2Details on market share changes in key segments.
3Management's outlook on competition and pricing strategies.
4Insights into cost management and operational efficiencies.
5Any commentary on regulatory challenges or opportunities.